Nadia Dac serves as Kyverna’s Chief Commercial Officer (CCO) and is responsible for overseeing the Company’s commercial operations, including the commercial strategy and execution for miv-cel (mivocabtagene autoleucel, KYV-101). Nadia brings more than 30 years of US and global commercial leadership in the biopharmaceutical industry and has deep experience successfully executing new product launches, scaling commercial organizations, and building high-performing teams.

Prior to joining Kyverna, Nadia served as CCO at Omeros Corporation, where she built and led the commercial organization for rare disease programs in hematologic and immune-mediated conditions, including the launch of Yartemlea®, the first FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Prior to Omeros, she served as CCO at Alder Biopharmaceuticals, Inc., where she led the commercial launch of Vyepti® in migraine prevention, prior to the company’s acquisition by Lundbeck.

Nadia also served as Vice President (VP) of Global Specialty Commercial Development at AbbVie, where she led portfolio strategy and optimization across rare disease and neuroscience, and as VP of Marketing at Auxilium Pharmaceuticals, Inc., where she oversaw the launch and commercialization of a portfolio of men’s health products. Earlier in her career, Nadia held commercial roles of increasing responsibility at Novartis and Biogen, and Pfizer. She also spent nearly a decade in neuroscience marketing and sales roles at Johnson & Johnson and Eli Lilly and Company. Nadia holds a B.S. in Marketing from Rutgers University.